SUFU 2011 - Duloxetine for treatment of post-prostatectomy stress urinary incontinence - Session Highlights

PHOENIX, AZ USA (UroToday.com) - This poster was a respective chart review of men treated with Duloxetine for the management of mild to moderate post prostatectomy UI from 2006 to 2010.

Mild to moderate stress UI was defined as urethral leakage with physical activity requiring five or fewer absorbent pads per day. They excluded men who had a history of pelvic radiation. Data collected included patient age, daily pad use, date of prostatectomy, and medication side effects. Questionnaires included the IIQ-7. All patients received Duloxetine 30 mg by mouth at bedtime for one week, then increased to 60 mg at bedtime thereafter. Patients were seen one month later to determine drug efficacy and side effects.

Thirty-five men were included in the study; mean age was 64.1 years. Average time from radical prostatectomy was 19.6 years. Daily pad usage decreased from 2.9 to 1.5. Following a one month trial of Duloxetine, 34% of men reported satisfactory stress UI improvement and requested to continue the drug. The drug was discontinued in 66% of men because of lack of efficacy and intolerable side effects or both. Reported side effects included fatigue, insomnia, nausea and dry mouth.

Conclusions were that Duloxetine improved post prostatectomy UI in 49% of men following a one month trial. However, only 34% of these patients were able to tolerate the drug.

 


Presented by R. Corey O'Connor, Amy Guise, Jonathan Vincent, Donald Neff, Peter Langenstroer, William Seem, and Michael Guralnick at the Society for Urodynamics and Female Urology (SUFU) 2011 Winter Meeting - March 1 - 5, 2011 - Arizona Biltmore, Phoenix, Arizona, USA

 


Reported for UroToday by Diane K. Newman, RNC, MSN, CRNP, FAAN and Continence Nurse Practitioner Specialist - University of Pennsylvania Medical Center.


 

 

The opinions expressed in this article are those of the UroToday.com Contributing Medical Editor and do not necessarily reflect the viewpoints of the Society for Urodynamics and Female Urology.


 

 

 

View Full SUFU 2011 Meeting Coverage